Viking Therapeutics ( ($VKTX) ) has risen by 7.76%. Read on to learn why. Viking Therapeutics has seen a notable 7.76% ...

We came across a bullish thesis on Viking Therapeutics, Inc. on r/wallstreetbets subreddit by Dritzz-9966. In this article, ...

Viking Therapeutics has strong R&D, dual-track obesity drugs, and solid cash runway. Click here to read an analysis of VKTX ...

Viking Therapeutics shares fall in Wednesday's after-hours session after the company reported financial results for the ...

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $30.0 and $60.0 for Viking Therapeutics, spanning the last three ...

With no revenue expected, VKTX's Q2 report is likely to have the spotlight on pipeline moves across its obesity drugs.

Viking Therapeutics is targeting two monster markets. David Jagielski (CRISPR Therapeutics): Biotech company CRISPR ...

Viking Therapeutics reported a solid financial standing with $808 million in cash, cash equivalents, and short-term investments. This strong cash position provides a substantial financial runway to ...

Viking Therapeutics, Inc. ( NASDAQ: VKTX) Q2 2025 Earnings Conference Call July 23, 2025 4:30 PM ET Brian Lian - President, CEO & Director Gregory Zante - Chief Financial Officer ...

Viking Therapeutics: Soaring Stock, But Is it Worth the Ride? Viking Therapeutics has been a hot stock in 2024, with its share price skyrocketing over 240% since the start of the year.

Eli Lilly is a leader in the weight loss drug market, generating blockbuster revenue. Viking Therapeutics recently launched a phase 3 trial for its weight loss candidate -- and could have a promising ...

In a report released yesterday, Naz Rahman from Maxim Group reiterated a Buy rating on Viking Therapeutics, with a price target of $70.00. The company’s shares closed yesterday at $33.50. Take ...